Abstract
In the early 1980s, an atypical beta-adrenergic receptor was discovered and subsequently called the beta3 -adrenoceptor (beta3 -AR). Agonists of the beta3 -AR were observed to simultaneously increase lipolysis, fat oxidation, energy expenditure and insulin action leading to the belief that this receptor might serve as an attractive target for the treatment of diabetes and obesity. In vivo studies lent credence to this postulate with the finding that stimulation of this receptor by selective agonists lead to glycemic improvements and weight loss in rodent models of diabetes and obesity. This lead to intensive research efforts directed at developing beta3 -AR selective agonists for the treatment of type 2 diabetes and obesity in humans. Unfortunately, endeavour been largely unsuccessful to date. Major obstacles have included the pharmacological differences between the rodent and human beta3 -AR, the lack of selectivity of previous compounds for the beta3 -AR over beta1 - / beta2 -ARs, and unsatisfactory oral bioavailability and pharmacokinetic properties. Cloning of the human beta3 -AR has allowed for the development of novel compounds targeted specifically at the human receptor. Encouraging data has emerged from clinical studies wherein CL-316,243, a highly selective, albeit rodent specific beta3 -AR agonist was observed to increase lipolysis, fat oxidation and insulin action in humans. More recently, beta3 -AR agonists directed at the human receptor are showing promising results in their ability to increase energy expenditure in humans following a single dose. However, they do not appear to be able to sustain their effects when administered chronically. Further clinical testing will be necessary, using compounds with improved oral bioavailability and potency, to help assess the physiology of the beta3 -AR in humans and its attractiveness as a potential therapeutic for the treatment of type 2 diabetes and obesity.
Keywords: Beta3 -Adrenoceptor Agonists, Anti-diabetic, Anti-obesity Drugs
Current Pharmaceutical Design
Title: Beta3 -Adrenoceptor Agonists as Anti-diabetic and Anti-obesity Drugs in Humans
Volume: 7 Issue: 14
Author(s): Christopher J. de Souza and Bryan F. Burkey
Affiliation:
Keywords: Beta3 -Adrenoceptor Agonists, Anti-diabetic, Anti-obesity Drugs
Abstract: In the early 1980s, an atypical beta-adrenergic receptor was discovered and subsequently called the beta3 -adrenoceptor (beta3 -AR). Agonists of the beta3 -AR were observed to simultaneously increase lipolysis, fat oxidation, energy expenditure and insulin action leading to the belief that this receptor might serve as an attractive target for the treatment of diabetes and obesity. In vivo studies lent credence to this postulate with the finding that stimulation of this receptor by selective agonists lead to glycemic improvements and weight loss in rodent models of diabetes and obesity. This lead to intensive research efforts directed at developing beta3 -AR selective agonists for the treatment of type 2 diabetes and obesity in humans. Unfortunately, endeavour been largely unsuccessful to date. Major obstacles have included the pharmacological differences between the rodent and human beta3 -AR, the lack of selectivity of previous compounds for the beta3 -AR over beta1 - / beta2 -ARs, and unsatisfactory oral bioavailability and pharmacokinetic properties. Cloning of the human beta3 -AR has allowed for the development of novel compounds targeted specifically at the human receptor. Encouraging data has emerged from clinical studies wherein CL-316,243, a highly selective, albeit rodent specific beta3 -AR agonist was observed to increase lipolysis, fat oxidation and insulin action in humans. More recently, beta3 -AR agonists directed at the human receptor are showing promising results in their ability to increase energy expenditure in humans following a single dose. However, they do not appear to be able to sustain their effects when administered chronically. Further clinical testing will be necessary, using compounds with improved oral bioavailability and potency, to help assess the physiology of the beta3 -AR in humans and its attractiveness as a potential therapeutic for the treatment of type 2 diabetes and obesity.
Export Options
About this article
Cite this article as:
de Souza J. Christopher and Burkey F. Bryan, Beta3 -Adrenoceptor Agonists as Anti-diabetic and Anti-obesity Drugs in Humans, Current Pharmaceutical Design 2001; 7 (14) . https://dx.doi.org/10.2174/1381612013397339
DOI https://dx.doi.org/10.2174/1381612013397339 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dehydroepiandrosterone (DHEA) for Depression: A Systematic Review and Meta-Analysis
CNS & Neurological Disorders - Drug Targets Peptide Self-assembly: From Toxins to Amyloid Fibrils and Nanotubes
Current Topics in Medicinal Chemistry Ca<sub>v</sub>1.3 Channels as Key Regulators of Neuron-Like Firings and Catecholamine Release in Chromaffin Cells
Current Molecular Pharmacology Serine Protease Inhibitor Kazal Type 1 (SPINK1): Beyond the Trypsin Inhibitor
Current Enzyme Inhibition Anti-Inflammatory Properties of Drugs from saffron crocus
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Women in LOVe: Lacto-Ovo-Vegetarian Diet Rich in Omega-3 Improves Vasomotor Symptoms in Postmenopausal Women. An Exploratory Randomized Controlled Trial
Endocrine, Metabolic & Immune Disorders - Drug Targets ROS Acts as a Double-Edged Sword in the Pathogenesis of Type 2 Diabetes Mellitus: Is Nrf2 a Potential Target for the Treatment?
Mini-Reviews in Medicinal Chemistry Developments in Selective Small Molecule ATP-Targeting the Serine/Threonine Kinase Akt/PKB
Mini-Reviews in Medicinal Chemistry INTRODUCTION TO THE ITALIAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacogenetics Strategies: From Candidate Genes to Whole-Genome Association Analysis. Exploratory or Confirmatory Studies?
Current Pharmacogenomics and Personalized Medicine Oral Infection and Vascular Disease
Vascular Disease Prevention (Discontinued) A Review on Phytochemistry and Pharmacology of Medicinal as well as Poisonous Mushrooms
Mini-Reviews in Medicinal Chemistry Recent Research Progress in Natural Bioactive Constituents against Lipid Metabolic Diseases
Current Topics in Medicinal Chemistry Peptide YY: A Potential Therapy for Obesity
Current Drug Targets Mitochondrial Biogenesis in Health and Disease. Molecular and Therapeutic Approaches
Current Pharmaceutical Design Targeted Nucleic Acid Delivery to Mitochondria
Current Gene Therapy Resident Cardiac Stem Cells
Current Pharmaceutical Design Regressing Left Ventricular Hypertrophy: The Role of Telmisartan and Other ARBs
Current Hypertension Reviews Chronic Stress Impacts on Olfactory System
CNS & Neurological Disorders - Drug Targets The Effects of the Endocrine Disruptors Dithiocarbamates on the Mammalian Ovary with Particular Regard to Mancozeb
Current Pharmaceutical Design